Dyne Therapeutics, Inc.
z-basivarsen
myotonic dystrophy type 1
Countdown
267days
Phase 2 readout · ~ Mar 31, 2027 estimated
What's at stake
Phase 2 trial results for z-basivarsen in myotonic dystrophy type 1 are due ~ Mar 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Topline data from the ACHIEVE REC are planned for the first quarter of 2027 to support a potential Biologics License Application (“BLA”) for U.S. Accelerated Approval in the third quarter of 2027.”